Drug Price Reform Concerns Novartis Pharma President
An Interview With Novartis's Marie-France Tschudin
Executive Summary
"We are definitely worried," Tschudin said about some US drug price reform proposals. She also spoke about competitive rebating and new growth opportunities for anchor brands.
You may also be interested in...
Novartis’s Tschudin On Launches, Drug Pricing And Lasting COVID Impacts
Two years into leading Novartis' largest business unit, Novartis Pharmaceuticals president Marie-France Tschudin talked to Scrip about the US launch of inclisiran, US drug price reform and other challenges and opportunities for the industry.
Medicare Price Negotiation Targeting Only Post-Exclusivity Drugs Proposed By Moderate House Democrats
Legislation authorizing the US government to directly negotiate drug prices with manufacturers failed to pass in one key House committee as a trio of Democrats joined Republicans to vote against advancing the policy.
Pharma On Its Back Foot As US Drug Price Reform Advances
Big pharma leaders warn of steep cuts to R&D and US jobs if US drug pricing reform legislation paves the way for direct government price negotiations.